Pharmaceutical Consulting Firms Driving Medical Tech Growth
The line between a drug and a device has been blurring for years. Combination products, connected inhalers, digital therapeutics, and diagnostic-linked treatments mean a growing share of pharma pipelines now depend on hardware, software, and data infrastructure that traditional drug development teams were never built to manage. This shift has pushed many life sciences companies to bring in outside expertise that understands both sides of that equation at once. Why Internal Teams Reach Their Limits Most pharmaceutical organizations are structured around the traditional drug development timeline: discovery, clinical trials, regulatory submission, launch. That structure works well for a small-molecule therapy moving through a familiar pathway, but it strains badly when a program also requires expertise in software validation, connected-device regulatory pathways, or real-world data integration. Internal teams built for one kind of product often lack the bandwidth or specialized knowledge ...